What information should be included when educating a client on repaglinide?

A. Hypoglycemia is a common side effect: Repaglinide is a meglitinide that stimulates rapid, short-acting insulin release from pancreatic beta cells, increasing the risk of hypoglycemia, especially if meals are skipped or delayed. Client education should emphasize recognizing early signs, carrying a source of glucose, and timing doses with meals to prevent severe hypoglycemia. B. Bruising may occur when taking this medication: Bruising is not a typical side effect of repaglinide. Unlike anticoagulants or antiplatelet agents, repaglinide does not affect platelet function or clotting pathways, so clients do not need to monitor for unusual bruising as part of routine education. C. Take this medication at night before bed: Repaglinide should be taken with meals, usually 0–30 minutes before eating, to match insulin secretion with postprandial glucose. Taking it at night without food increases the risk of hypoglycemia, particularly during prolonged fasting or sleep. D. Stop taking if you experience hyperglycemia: Experiencing high blood glucose does not warrant abrupt discontinuation of repaglinide. Instead, the client should notify the healthcare provider for dose adjustment or evaluation of adherence, diet, or additional therapy while continuing the medication safely.